Diabetes medication Linagliptin 668270-12-0_Viwit

Product

/

Products and Services

/

Active pharmaceutical ingredients

/

Active pharmaceutical ingredients

/

Diabetes medication Linagliptin 668270-12-0

News Center

Viwit Pharmaceutical Co., Ltd. participated in CPHI Worldwide 2022 held in Frankfurt Germany from November 1st to November 3rd. 2022-11-09 12:43:00

As the world's largest pharmaceutical industry exhibition, CPHI has been successfully held for 30 years. It displays the entire pharmaceutical supply chain, from API, P-MEC to FDF. It becomes the largest annual gathering of pharmaceutical professionals all over the world. Viwit met old friends and new business partners at CPHI. We displayed a wonderful enterprise image with our products and services, and promoted our international business through CPHI.

Viwit participants in CPhI China 2019, booth: W2B28 2019-06-18 01:34:00

CPhI China 2019 will be held at Shanghai New International Expo Center on June 18-20, 2019. Welcome to patronage of Viwit, booth number: W2B28. If you would like to make an appointment in advance, please email us at service@viwit.com.

CPhI India 2018, Booth No. 4.H15 2018-12-12 01:34:00

CPhI India 2018, Booth No. 4.H15 CPhI India 2018 will take place on Dec. 12 - Dec. 14, 2018 at India Expo Center, India. Please visit us on CPhI India 2018, Booth No. 4.H15. If you would like to make an appointment, please send an e-mail to service@viwit.com.

Welcome participants in CPhI India 2018, booth number: 4.H15 2018-12-12 01:32:00

Welcome participants in CPhI India 2018, booth number: 4.H15 CPhI India 2018 will be held from December 12th to 14th, 2018 at the Expo Center in Delhi, India. Welcome to patronage of Viwit, booth number: 4.H15. If you want to make an appointment in advance, please send an email to service@viwit.com

Congratulations to Viwit Pharmaceutical Co., Ltd. for passing GMP certification of Health Canada 2018-10-11 01:32:00

In September 2018, Viwit's API factory in Tengzhou, Shandong Province ushered in a five-day GMP audit by Health Canada. In the end, Welcome successfully completed the GMP inspection by Health Canada and achieved excellent results. Any regulatory inspection is a challenge, but it is also a great opportunity to demonstrate your capabilities. Viwit has always adhered to the concept of cGMP standards and is committed to following high standards of quality management system. The successful on-site inspection by Health Canada is another milestone achievement by Viwit as a world-leading pharmaceutical and health company. Viwit will continue to follow the cGMP standards for each operation procedure to provide the market with safer and higher quality products.

Welcome participants in CPhI Worldwide 2018, booth number: 7A80 2018-10-09 01:33:00

CPhI Worldwide 2018 will be held on October 9-11, 2018 at the Madrid International Convention and Exhibition Center in Spain. Welcome to patronage of Viwit, booth number: 7A80. If you want to make an appointment in advance, please send an email to service@viwit.com

Diabetes medication Linagliptin 668270-12-0

【Alias】 8-[(3R) -3-amino-1-piperidinyl] -7- (2-butynyl) -3,7-dihydro-3-methyl-1-[(4-methyl- 2-quinazolinyl) methyl] -1H-purine-2,6-dione
【Catalog Number】AP4700
【CAS #】668270-12-0
【Molecular Formula】C25H28N8O2
【Molecular Weight】472.54

English Name : Linagliptin

CAS# : 668270-12-0





产品描述

[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]

Alias	8-[(3R) -3-amino-1-piperidinyl] -7- (2-butynyl) -3,7-dihydro-3-methyl-1-[(4-methyl- 2-quinazolinyl) methyl] -1H-purine-2,6-dione
Catalog Number	AP4700
CAS #	668270-12-0
Molecular Formula	C₂₅H₂₈N₈O₂
Molecular Weight	472.54
Structural Formula
Product Introduction CAS 668270-12-0 US-DMF No. 29692	Lilaliptin, English name Linagliptin, American Chemical Abstracts registration number cas 668270-12-0. Lillaritin (cas 668270-12-0) was approved by the FDA on May 2, 2011 to improve dietary and exercise control of blood glucose levels in people with type 2 diabetes. Lilaridine improves patients' glycemic control by inhibiting dipeptidyl peptidase-4 (DPP-4).

扫二维码用手机看

Previous：

Diabetes medication Sitagliptin Phosphate Monohydrate 654671-77-9

Next：

Diabetes medication Vildagliptin 274901-16-5



search

Confirm

Close

About Us

R&D and Innovation

Products

Innovation

Sustainable

News Center

Join Us

Contact Us

VIWIT 沪ICP备12014533号-2

EN

中文